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ABSTRACT
Naïve FoxP3-expressing regulatory T-cells (Tregs) are essential to control 
immune responses via continuous replenishment of the activated-Treg pool with 
thymus-committed suppressor cells. The mechanisms underlying naïve-Treg 
maintenance throughout life in face of the age-associated thymic involution remain 
unclear. We found that in adults thymectomized early in infancy the naïve-Treg pool is 
remarkably well preserved, in contrast to conventional naïve CD4 T-cells. Naïve-Tregs 
featured high levels of cycling and pro-survival markers, even in healthy individuals, 
and contrasted with other circulating naïve/memory CD4 T-cell subsets in terms 
of their strong γc-cytokine-dependent signaling, particularly in response to IL-7. 
Accordingly, ex-vivo stimulation of naïve-Tregs with IL-7 induced robust cytokine-
dependent signaling, Bcl-2 expression, and phosphatidylinositol 3-kinase (PI3K)-
dependent proliferation, whilst preserving naïve phenotype and suppressive capacity. 
Altogether, our data strongly implicate IL-7 in the thymus-independent long-term 
survival of functional naïve-Tregs, and highlight the potential of targeting the IL-7 
pathway to modulate Tregs in different clinical settings.
INTRODUCTION
FoxP3-expressing regulatory T-cells (Treg) maintain 
tolerance to self and to the environment, and are central 
players in the control of immune responses in general 
[1]. Notwithstanding their relevance in limiting immune-
mediated pathology, and their therapeutic potential, 
research focused on human Treg homeostasis has been 
scarce [2]. Human Tregs comprise a compartment of 
thymus-generated naïve-like cells (naïve-Tregs) that 
continuously replenish the pool of fully-suppressive 
activated Tregs expressing memory markers [1-7]. The 
mechanisms governing naïve-Treg homeostasis, in parallel 
with age-associated thymic involution, remain largely 
unknown. Moreover, the investigation of naïve-Treg 
homeostasis has been hampered by the difficulty in clearly 
identifying this subset in murine models [8].
The establishment and maintenance of the human 
naïve T-cell compartment is known to rely on both thymic 
output and peripheral expansion, with their relative 
contributions still the subject of intense debate. Increasing 
evidence points to a major contribution of peripheral 
proliferation in order to explain the relatively stable size 
of the naïve compartment in adulthood despite thymic 
involution [9, 10]. 
Individuals submitted to total thymectomy in early 
infancy due to corrective cardiac surgery provide an ideal 
clinical setting to address the peripheral contribution to 
long-term maintenance of naïve T-cell subsets. Contraction 
of the entire naïve compartment upon thymectomy has 
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been consistently reported, confirming the central role 
of the thymus [11-14]. Notwithstanding this, distinct 
homeostasis of the naïve-Treg and conventional naïve 
(naïve-Tconv) CD4 T-cell compartments have been 
suggested by a longitudinal study that showed naïve-Treg 
preservation up to 1 year post-thymectomy [15], although 
long-term data are lacking. 
Peripheral homeostasis of naïve-Tconvs relies upon 
a slow rate of cell-turnover resulting from both cytokine-
driven proliferation, and TCR-stimulation by low-affinity 
self-peptides [16]. Additionally, naïve-Tconv homeostasis 
is known to rely on pro-survival factors, such as Bcl-
2, which are up-regulated by homeostatic cytokines, 
particularly IL-7 [16, 17]. 
Naïve-Tregs are characterized by high-affinity for 
self-peptides, and by rapidly differentiating into memory-
Tregs upon T-cell receptor (TCR)-stimulation [1-6]. Thus, 
major histocompatibility (MHC)-self peptide stimulation 
is likely to result in loss of their naïve phenotype. On the 
other hand, in terms of the contribution of cytokine-driven 
proliferation, naïve-Tregs express low levels of receptors 
for the main homeostatic cytokines. CD25, the α-chain of 
the IL-2 receptor, is expressed at only intermediate/dim 
levels [1], questioning whether naïve-Tregs, like their 
memory counterparts, depend on IL-2 [2]. Moreover, 
Tregs per se typically express low levels of the α-chain 
of the IL-7 receptor (IL-7Rα), and there are controversial 
reports on the IL-7 impact on human and murine Tregs 
[18-22]. 
We investigated here the impact of IL-7 and IL-2 
on peripheral naïve-Tregs from blood and secondary 
lymphoid organs (SLO), as well as on mature FoxP3+ 
thymocytes, and provide evidence for a role of IL-7 in 
human naïve-Treg homeostasis. We show for the first 
time that naïve-Tregs feature much higher levels of the 
pro-survival molecule Bcl-2 and significantly higher 
turnover than naïve-Tconvs in healthy individuals. These 
parameters further increased in the absence of thymic 
replenishment, ensuring the long-term maintenance of 
the naïve-Treg compartment in total thymectomized 
individuals. 
RESULTS
Preservation of the naïve-Treg compartment 
following thymus removal
Adults submitted to total thymectomy early in 
life provide a unique setting to investigate human naïve 
compartment homeostasis. However, published studies 
have been hampered by the lack of clear information 
regarding possible residual thymic activity that can 
result from either ectopic thymus or post-thymectomy 
regeneration [11, 12, 14, 23]. We applied here strict criteria 
to exclude residual thymic activity based on detailed 
surgical reports and single-joint TCR excision circles 
(sjTREC) levels clearly below the lowest level observed 
in healthy adults (Table 1). sjTRECs are by-products of 
TCR rearrangements during T-cell development that are 
progressively lost as cells divide in the periphery, and 
thus used to identify recent thymic emigrant cells [24]. 
Adults, with a median of 21 years (18-24.5) after total 
thymectomy, were compared with age-matched healthy 
individuals (Table 1).
We observed a significant decrease in circulating 
naïve-Tconvs, both in frequency within CD4 T-cells (P = 
0.0042; Supplementary Figure 1A) and absolute numbers 
(P = 0.0026; Figure 1), in agreement with previous data 
from other thymectomized cohorts [11-14]. Conversely, 
the naïve-Treg pool size was preserved, as compared to 
healthy subjects (Figure 1 and Supplementary Figure 1A). 
The healthy cohort spanned an age period associated 
with relatively stable thymic function and naïve-Treg 
numbers [6], and the size of the circulating naïve-Treg 
pool was within the range previously described [4-6]. 
We sorted naïve-Tregs, and confirmed that their FOXP3 
mRNA expression levels were comparable to those found 
in memory-Tregs (4526-21104 versus 1540-14363 relative 
copy numbers, respectively, n = 3 healthy adults), and 
much higher than those in naïve-Tconvs (34-115 relative 
copy numbers), confirming them as bona fide Tregs [1]. 
Circulating naïve-Tregs were confirmed to have a 
truly naïve phenotype both in healthy and thymectomized 
subjects, based on the expression of a panel of naïve 
markers and reduced CD95 expression, as well as to 
express Treg function-associated markers (CTLA-4, HLA-
DR, CD39) at lower levels than memory-Tregs (Figure 
1 and Supplementary Figure 1B). Although Helios has 
been proposed as a marker of thymus-derived Tregs, we 
showed that in both cohorts a significant proportion of 
circulating naïve-Tregs lacked Helios expression (Figure 
1 and Supplementary Figure 1B), as already observed 
in human mature FoxP3+ CD4 single-positive (CD4SP) 
thymocytes (Supplementary Figure 1C), questioning 
its usefulness as a marker of thymic-derived Tregs [25]. 
Regarding the CD31+ subset, a population known to be 
enriched in recent thymic emigrants [16], no significant 
contraction was observed within naïve-Tregs of 
thymectomized, as compared to healthy individuals (P 
= 0.1708, Supplementary Figure 1B), in contrast to the 
significant reduction observed within naïve-Tconvs (P = 
0.0122, Supplementary Figure 1B). This finding suggests 
that distinct homeostatic mechanisms are operating in the 
two naïve compartments upon thymectomy. Interestingly, 
we have previously shown that IL-7 up-regulates CD31 
expression [17], further validating the importance of 
investigating the impact of IL-7 on naïve-Tregs, as 
detailed below. 
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In order to investigate the mechanisms underlying 
the preservation of the naïve-Treg compartment, we 
quantified the expression levels of markers of cell 
survival and cell cycling in thymectomized, as compared 
to healthy individuals. Bcl-2 expression was significantly 
higher, supporting a contribution of increased naïve-
Treg survival to their maintenance upon thymectomy (P 
= 0.0143; Figure 1). Additionally, significantly higher 
frequencies of cycling-cells, as assessed by Ki-67, were 
documented (P = 0.0009; Figure 1). The degree of Bcl-
2 increase in thymectomized was comparable in the two 
naïve compartments, whereas the increase in Ki-67+ cell 
frequency was much more striking within naïve-Tregs (4-
fold) than within naïve-Tconvs (1.7-fold), supporting an 
important contribution of increased cell-turnover to the 
better preservation of the naïve-Treg compartment. 
Altogether, our data indicate that naïve-Tregs are 
preserved in adults submitted to total thymectomy in 
early infancy, mainly through increased homeostatic 
proliferation.
High steady-state turnover of the naïve-Treg 
compartment
The finding of a preserved naïve-Treg compartment 
in thymectomized adults prompted us to further investigate 
the mechanisms underlying naïve-Treg homeostasis under 
steady-state conditions in healthy young adults with stable 
thymic output.
We found that naïve-Tregs displayed significantly 
higher levels of Bcl-2 than both naïve-Tconvs and 
memory-Tregs (Figure 2A), suggesting that enhanced 
survival plays a major role in their maintenance. 
Therefore, in this respect, naïve-Tregs are distinct from 
memory-Tregs, which have been shown to have a pro-
apoptotic profile [1, 4]. 
Additionally, naïve-Tregs featured a much higher 
in-vivo turnover than naïve-Tconvs (Figure 2A), with 
significantly elevated proportion of cycling-cells 
(2.23%[1.12-4.75] versus 0.17%[0.10-0.29], P < 0.0001). 
Thus, although naïve-Tregs are frequently labeled as 
“quiescent” as opposed to memory-Tregs, we show here 
that they featured levels of cycling comparable to those 
found in memory-Tconvs (Figure 2A).
Homeostatic naïve-Tconv proliferation occurs 
mainly in SLO [16]. We performed a parallel study of 
blood and tonsils, used here as an example of SLO due 
to ease of access to clinical samples. Tonsil naïve-Tregs 
featured a much higher proportion of cycling-cells than 
blood naïve-Tregs (Figure 2B). Notably, the fold-increase 
in cycling-cells in tonsils as compared to blood was 
much more striking in the naïve-Treg than in the naïve-
Tconv compartment (4-fold versus 2-fold, respectively). 
The presence of naïve-Tregs expressing Ki-67 in tonsil 
tissue was further confirmed by immunofluorescence 
(Supplementary Figure 2A). Additionally, we showed 
that naïve-Tregs from freshly-collected tonsils 
consistently entered S-phase at higher rates than naïve-
Tconvs, as estimated by the ex-vivo incorporation of 
5-ethynyl-2’-deoxy-uridine (EdU), a thymidine analogue 
(Supplementary Figure 2B; 12 hours incubation: naïve-
Treg: 1.23-1.70%; naïve-Tconv: 0.37-0.42%; n = 3). Of 
note, in tonsils, naïve-Tregs featured significantly higher 
proportion of Ki-67+ cells than naïve-Tconvs (Figure 2B), 
as well as Bcl-2 MFI (mean fluorescence intensity; range 
2777-3161 versus 1873-1992, n = 3, respectively). These 
results suggest that SLO may provide appropriate niches 
for naïve-Treg homeostatic proliferation. 
Overall, our data show that, in healthy young 
adults, naïve-Tregs featured markers of enhanced survival 
and increased turnover in comparison to naïve-Tconvs, 
supporting an important contribution of peripheral 
proliferation to the maintenance of the naïve-Treg 
compartment.
Ex-vivo evidence for ongoing naïve-Treg response 
to IL-7
Next, we investigated the putative contribution of 
γc-cytokines to the increased turnover and survival of 
naïve-Tregs. Ex-vivo levels of pSTAT5, a downstream 
marker of both IL-7 and IL-2-mediated signaling, were 
significantly higher in naïve-Treg than in naïve-Tconv and 
memory CD4 subsets, analyzed in freshly-collected whole 
blood from healthy subjects (Figure 3A), irrespectively 
of the levels of expression of IL-7Rα and IL-2Rα 
(Supplementary Figure 1B). Additionally, we stimulated 
purified CD4 T-cells with increasing concentrations of IL-7 
or IL-2, and clearly showed that naïve-Tregs responded to 
both cytokines, in a dose-dependent manner (Figure 3B 
Figure 1: Preservation of the naïve-Treg compartment 
following thymus removal. Circulating naïve-Treg and 
naïve-Tconv counts; as well as % of cycling-cells, and Bcl-2 
MFI within these subsets in healthy and thymectomized adults; 
each symbol represents one individual; bars represent median; 
significant P-values of comparisons within each subset are 
shown. 
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and Supplementary Figure 3A). Our data extend previous 
human and murine studies on the ability of Tregs to 
phosphorylate STAT5 in response to IL-7 in-vitro [20, 26-
28], through the comparison of naïve and memory Tregs, 
as well as their FoxP3 negative counterparts.
Since IL-7 signaling induces the down-regulation of 
its receptor [17], we reasoned that the level of recovery 
of IL-7Rα expression upon IL-7 deprivation would reflect 
the extent of ongoing IL-7 signaling in-vivo. IL-7Rα 
expression levels were quantified in purified CD4 T-cells 
from healthy subjects following 24 hours in different 
culture conditions (Figure 3C and Supplementary Figure 
3B). Naïve-Tregs featured a significant recovery of IL-
7Rα expression in the absence of IL-7 (culture in serum 
free medium), as compared to ex-vivo levels, in agreement 
with a significant ongoing IL-7 response. Notably, IL-
7Rα expression was relatively preserved in the presence 
of autologous serum (IL-7 levels range: 15.8-23.5pg/ml). 
Moreover, the possible contribution of IL-2, either derived 
from serum or produced by cells in culture, was excluded 
by documenting a lack of impact of IL-2 blockade. 
Addition of exogenous IL-7 (10ng/ml) or IL-2 (20IU/ml) 
led to the expected down-regulation of IL-7Rα [29]. 
In conclusion, we showed that naïve-Tregs featured 
high ex-vivo pSTAT5 levels, and recovered IL-7Rα 
expression after IL-7 deprivation, supporting their ongoing 
response to IL-7 in-vivo.
Preserved naïve phenotype, Treg-markers and 
suppressive capacity upon naïve-Treg response to 
IL-7
We subsequently investigated the impact of IL-7 
on naïve-Treg phenotype and suppressive capacity. For 
this purpose, total naïve CD4 T-cells were purified from 
freshly-collected blood of healthy donors, and cultured 
for up to 13 days in the presence of IL-7 or IL-2, using 
conditions previously optimized in our laboratory [17]. 
Analysis was performed within naïve-Tregs and naïve-
Tconvs defined according to their FoxP3 expression, as 
illustrated in Figure 4A.
We confirmed that FoxP3 was not induced in naïve-
Tconvs in the presence of IL-7, using sorted naïve-Tconvs 
cultured alone with IL-7, and showing no increase in 
FoxP3 expression either at the protein level, by flow-
cytometry (Figure 4B), or at the transcriptional level 
by real-time PCR (ex-vivo range 34-115 versus 14-62 
FOXP3 relative copy numbers after 13 day-culture, n = 
3). FoxP3 induction was also not observed in cultures of 
purified naïve-Tconvs with IL-2 (data not shown). This is 
in agreement with the requirement for TCR stimulation for 
de novo induction of FoxP3 in conventional CD4 T-cells 
[1]. 
Importantly, despite the clear impact of both IL-7 
Table 1: Characterization of the cohorts
Healthy Thymectomized
Number 22 7
Age, years 21 [18-30] 24 [22-27]
Thymectomy, month of age NA 23 [12-72]
sjTRECs/µl 16.6 [4.1-39.3] 0.5 [0.1-1.8]a
Lymphocytes/µl 2413 [1430-3502] 2010 [933-2618]
% CD4 T-cells 40 [29-52] 43 [23-47]
% Naïveb in CD4 40 [29-58] 15 [9-49]a
% FoxP3+ in CD4 2.9 [1.2-5.4] 4.1 [3.0-5.6]
FoxP3+  cells/µl 21 [9-51] 28 [11-39]
Serum IL-7, pg/ml 15 [7-23] 14 [8-20]
Data are presented as median with limits in square brackets. NA - not applicable. aP<0.0001. bNaïve cells 
defined as CCR7+CD45RO─ 
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and IL-2 on the recovery of naïve-Tregs in cultures of total 
naïve CD4 T-cells, neither cytokine was able to maintain 
sort-purified naïve-Tregs when they were cultured alone 
(Figure 4C). This finding revealed a requirement for 
naïve-Tregs to interact with naïve-Tconvs to ensure their 
survival, which was not overcome by the addition of IL-2 
(Figure 4C). These data precluded purified naïve-Treg 
culture in isolation. 
Of note, the overall proportion of naïve-Tregs 
within total naïve CD4 T-cells significantly increased 
upon 13 day-culture with IL-7 (from 0.99%[0.60-1.43] to 
2.15%[1.29-3.21], P = 0.0048, n = 16). This increase was 
more evident upon culture with IL-2 (7.94%[3.65-11.75], 
P = 0.0005), likely due to the reduced impact of IL-2 on 
naïve-Tconvs (Figure 4C).
As illustrated in Figure 4D, FoxP3+ cells maintained 
their naïve phenotype following 13 day-culture with 
either IL-7 or IL-2. Our previous work showed that 
IL-7 increases CD31 expression in naïve CD31+ CD4 
T-cells [17]. Here, we showed that naïve-Tregs cultured 
in the presence of IL-7 up-regulated CD31 MFI to levels 
comparable to naïve-Tconvs (fold-increase: 2.17[1.45-
3.69] versus 2.17[1.73-2.46], P = 0.4333, respectively; 
Figure 4D). Moreover, naïve-Tregs up-regulated CD25 
(fold-increase: 3.85[3.29-6.01], Figure 4E), and down-
Figure 3: Ex-vivo evidence for ongoing naïve-Treg 
response to IL-7. A. Representative histogram of ex-vivo 
pSTAT5 levels in circulating naïve-Tregs and naïve-Tconvs, 
with graph showing pSTAT5 MFI within these and counterpart 
memory CD4 T-cell subsets; comparison of pSTAT5 levels only 
revealed significant differences between naïve-Tregs and all 
the other subsets (* P < 0.05; n = 6). B. Analysis of pSTAT5 
MFI within gated naïve-Tregs upon in-vitro stimulation with 
increasing concentrations of IL-7 or IL-2; each symbol represents 
one individual. C. IL-7Rα MFI within naïve-Tregs analyzed ex-
vivo and after 24 hour-culture without serum or supplemented 
with 40% autologous serum alone or with IL-7 (n = 6); as well as 
with IL-2, anti-IL-2 blocking monoclonal antibody, or isotype-
control (n = 3); * P < 0.05 as compared to ex-vivo levels. 
Figure 2: High steady-state turnover of the naïve-
Treg compartment. A. Bcl-2 MFI and % of cycling-cells, 
within circulating CD4 T-cell subsets; each dot represents one 
individual; bars represent median; significant P-values are 
shown. B. % of cycling-cells within naïve-Tregs and naïve-
Tconvs from matched blood and tonsil samples (each symbol 
represents one child: 2years/open, 6years/grey, and 7years/
black). 
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Figure 4: Evidence of naïve-Treg response to IL-7 while preserving their naïve and suppressive phenotype. A. 
Representative contour-plots of FoxP3 and CD25 expression within total naïve CD4 T-cells ex-vivo (dØ) and upon 13 day-culture with IL-7 
or IL-2. B. Illustrative histogram demonstrating absence of FoxP3 induction in purified naïve-Tconvs following 13 day-culture with IL-7. 
C. Cell recovery upon 13 day-culture with IL-7 or IL-2 of total naïve CD4 T-cells (n = 11), purified naïve-Tregs (n = 3) or purified naïve-
Tconvs (n = 3); graph shows median and interquartile range or range (purified populations). E.-F. Analysis of naïve-Tregs and naïve-Tconvs 
ex-vivo and post-13 day-culture of naïve CD4 T-cells with IL-7 or IL-2 showing representative contour-plots of CD31/CD45RA expression 
(D), and graphs of MFI of CD31 (D), CD25 (E), and IL-7Rα (F); each dot represents one individual; bars represent median; comparisons 
done within each subset; significant P-values are shown. G. Illustrative histograms of CTLA-4, Helios, HLA-DR, CD39, Tim-3, PD-1 and 
PD-L1 expression within naïve-Tregs and naïve-Tconvs ex-vivo and post-13 day-culture with IL-7 or IL-2 (one/3-14). H. IL-2, IL-4, IL-17 
and IFN-γ production after short-term PMA/Ionomycin stimulation ex-vivo and post-13 day-culture with IL-7 or IL-2 (one/3). I. Illustrative 
histograms of CFSE expression within naïve-Tconvs cultured alone or with naïve-Tregs pre-incubated with medium alone, IL-7 or IL-2 
(numbers represent % of cells that divided at least once); graph shows % of suppression of naïve-Tconv proliferation in 3 individuals. 
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regulated IL-7Rα (fold-reduction: 0.43[0.23-0.67], Figure 
4F) upon IL-7 stimulation, although less markedly than 
naïve-Tconvs (11.54[7.80-14.96], P < 0.0001 for CD25; 
and 0.21[0.15-0.27], P = 0.0058 for IL-7Rα expression). 
These findings support an ability of naïve-Tregs to respond 
to IL-7.
The impact of IL-2 on naïve-Tregs followed a 
similar pattern, albeit significantly less striking than that 
observed for IL-7 (Figure 4D-F). Conversely, in naïve-
Tconvs both CD25 and CD31 expression levels were 
unaltered in response to IL-2, whereas IL-7Rα expression 
increased (Figure 4D-4F), possibly due to a dominant 
effect of IL-7 deprivation [17, 29]. 
Concerning Treg function-associated markers, 
naïve-Treg FoxP3 MFI (ex-vivo: 778[650-1009], n = 16) 
significantly increased upon culture with IL-7 (1166[863-
1522], P = 0.0214), and even more so with IL-2 
(1229[902-1916], P = 0.0280 as compared to ex-vivo, P = 
0.0362 as compared to IL-7). Furthermore, we observed 
a sustained or moderate increase in CTLA-4, CD39 and 
HLA-DR expression upon culture with either IL-7 or 
IL-2 (Figure 4G), suggesting maintenance of regulatory 
function. Additionally, IL-7 induced a major up-regulation 
of PD-L1, but not PD-1, on both naïve subsets (Figure 
4G). 
Importantly, naïve-Tregs remained unable to 
produce IL-2, IL-4, IL-17 or IFN-γ after 13 day-culture 
in the presence of IL-7 or IL-2, as evaluated upon further 
short-term stimulation with PMA plus Ionomycin (Figure 
4H). 
Figure 5: IL-7 induced naïve-Treg survival and proliferation. A.-D. Analysis of naïve-Tregs and naïve-Tconvs ex-vivo (dØ) and 
post 13 day-culture of purified naïve CD4 T-cells with IL-7 or IL-2 or IL-7 plus anti-IL-2 blocking monoclonal antibody: (A) Representative 
contour-plots of Bcl-2 and Ki-67 expression; graphs show Bcl-2 MFI (B) and % of cycling-cells (C), bars represent median; significant 
P-values of comparisons within each subset are shown; (D) Contour-plots illustrating the impact of IL-7 or IL-2 on EdU incorporation 
by naïve-Tregs (final 12 hours-culture, n = 2). E. Illustrative histograms of Bcl-2 and Ki-67 expression within gated FoxP3+ or FoxP3─ 
cells ex-vivo and post 7 day-culture of purified CD4SP thymocytes with IL-7 or IL-2 (one/3). F. Impact of the PI3K-inhibitor (LY294002), 
mTOR-inhibitor (rapamycin), or vehicle control (DMSO), on naïve CD4 T-cells upon 7 day-culture with IL-7; graphs show % of naïve-
Treg and change in cell recovery, Bcl-2 MFI and % of cycling-cells within naïve-Tregs and naïve-Tconvs, as compared to ex-vivo levels; 
each color represents one individual.
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Finally, we asked whether exposure to IL-7 impairs 
the suppressive capacity of naïve-Tregs. For this purpose 
we sorted naïve-Tregs and compared their suppressive 
capacity upon 4 hours pre-incubation with culture medium 
alone or supplemented with IL-7 or IL-2. We observed 
that upon treatment with either cytokine, naïve-Tregs 
maintained their ability to suppress autologous naïve-
Tconv proliferation in response to TCR stimulation 
(Figure 4I). 
Altogether, these results support an ability of naïve-
Tregs to respond to IL-7 whilst maintaining both their 
naïve and suppressive phenotype. 
IL-7 induced naïve-Treg survival and proliferation 
We then asked whether IL-7 induces the expression 
of markers of survival (Bcl-2) and cell cycling (Ki-67) 
in naïve-Tregs. We observed a clear induction of Bcl-2 
expression in naïve-Tregs cultured in the presence of IL-7 
(Figure 5A-B), although less marked than in naïve-Tconvs 
(fold-increase: 3.02[2.33-3.72] versus 3.93[3.29-5.05], 
respectively, P < 0.0001). Bcl-2 up-regulation in naïve-
Tregs was significantly higher upon IL-7 stimulation than 
with IL-2 (Figure 5A-5B), using optimal concentrations of 
both cytokines [17].
Additionally, IL-7 induced cycling of naïve-Tregs 
(Figure 5A and 5C). The proportion of cells expressing 
Ki-67 (21.06%[9.62-40.40]) was higher than that observed 
within naïve-Tconvs (13.92%[5.11-17.63], P = 0.0186), 
and within naïve-Tregs cultured with IL-2 (7.31%[1.74-
9.35], P = 0.0019). These findings are even more striking 
considering the much higher IL-7Rα expression levels 
on naïve-Tconvs (Supplementary Figure 1B). We further 
showed that IL-7 was superior to IL-2 in promoting 
naïve-Treg entry into cell-cycle, via assessment of the 
frequency of EdU-incorporating cells in the last 12 
hours of the culture (Figure 5D). Proliferative studies 
using carboxyfluorescein succinimidyl ester (CFSE)-
labeled cells were not performed, as we have previously 
demonstrated that this approach does not reproducibly 
reveal cytokine-mediated proliferation of naïve CD4 
T-cells [17]. 
Importantly, as shown in Figure 5A, IL-7 induction 
of Bcl-2 and cell cycling was unaltered in the presence 
of an anti-IL-2 blocking monoclonal antibody, thus 
supporting a major role for IL-7 in the maintenance of 
naïve-Treg homeostasis independently of IL-2.
Human FoxP3+CD4SP thymocytes were already 
able to proliferate in culture, and to up-regulate Bcl-2 
in response to IL-7 (Figure 5E), in agreement with our 
previous data showing an increase of pSTAT5 in FoxP3+ 
thymocytes upon stimulation with IL-7 [30]. 
Finally, we investigated whether the signaling 
pathways involved in IL-7 response differed between 
naïve-Tregs and naïve-Tconvs. IL-7 signaling uses both 
JAK3/STAT5 and PI3K/Akt pathways to promote T-cell 
survival and proliferation [17]. We have previously 
demonstrated that IL-7-mediated naïve CD4 T-cell 
proliferation, but not Bcl-2 up-regulation, critically 
depends upon PI3K activity [17]. On the other hand, 
Treg metabolism is known to rely on mammalian target 
of rapamycin (mTOR) [2]. To investigate the relative 
importance of these pathways, we added the cell permeable 
PI3K-specific inhibitor (LY294002) or mTOR inhibitor 
(rapamycin) to naïve CD4 T-cells cultured with IL-7 or 
IL-2. A 7 day-culture assay was selected to avoid possible 
deleterious impact of long-term exposure to the inhibitors, 
and was found to be sufficient to reveal Bcl-2 and Ki-67 
induction albeit at lower levels than after 13 day-culture 
(Figure 5F). Inhibition of the PI3K pathway led to a major 
decrease in naïve-Treg recovery and proliferation upon 
stimulation with IL-7. Conversely, Bcl-2 expression was 
not significantly altered. Similar trends were observed 
upon mTOR inhibition, supporting its participation in the 
signaling cascade leading to proliferation. Moreover, the 
addition of these inhibitors to IL-2 stimulated cultures 
generated comparable profiles in naïve-Tregs, indicating 
that these pathways are utilized by both cytokines (data 
not shown). 
Overall, our in-vitro data reveal that both IL-7 and 
IL-2 are able to promote proliferation of naïve-Tregs 
via activation of PI3K/mTOR signaling, and that IL-7 
promotes the survival and proliferation of FoxP3+ mature 
thymocytes and circulating naïve-Tregs.
DISCUSSION
Naïve-Tregs are thymus-committed regulatory T 
cells with a high degree of self-reactivity that continuously 
replenish the activated memory-Treg pool. Our finding of 
a preserved naïve-Treg compartment in adults submitted 
to total thymectomy in infancy support the relevance of 
peripheral mechanisms to ensure naïve-Treg homeostasis. 
We further showed that in steady-state conditions human 
naïve-Treg homeostasis occurs through a combination of 
high turnover rate and extended survival mediated by IL-7 
and/or IL-2, based on the following evidence: 1) higher 
levels of the pro-survival molecule Bcl-2 and proportion of 
cycling-cells than naïve-Tconvs in both blood and tonsils; 
2) the highest ex-vivo levels of pSTAT5 as compared to 
other naïve/memory CD4 T-cell subsets, which further 
increases, in a dose-dependent manner, following IL-7 
or IL-2 stimulation; 3) recovery of IL-7Rα expression 
upon IL-7 deprivation, consistent with an ongoing in-vivo 
response to IL-7; 4) response to IL-7 and IL-2 in culture 
indicated by up-regulation of Bcl-2, and induction of 
PI3K/mTOR-mediated proliferation; and 5) maintenance 
of naïve and suppressive phenotype upon exposure to IL-
7. Additionally, we showed that naïve-Treg precursors, 
namely FoxP3+CD4SP thymocytes, already proliferate and 
up-regulate Bcl-2 in response to IL-7 stimulation in-vitro. 
Thus, our results challenge the assumption that 
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naïve-Tregs are a quiescent population in steady-state 
conditions in non-lymphopenic individuals [1]. Human 
naïve-Tregs have been shown to feature a functional 
and molecular profile partially overlapping with both 
memory-Tregs and naïve-Tconvs [1, 4, 6]. Regarding 
their homeostasis, as for the memory compartment we 
found a much higher cell-turnover in naïve-Tregs than in 
naïve-Tconvs, suggesting an intrinsic propensity of Tregs 
to enter cell cycle. On the other hand, in agreement with 
their naïve character, naïve-Treg turnover was lower and 
Bcl-2 levels higher than in their memory counterparts. 
Additionally, similar pathways were apparently operating 
in response to IL-7 in naïve-Tregs and naïve-Tconvs. 
In fact, we revealed here, for the first time, a 
role for IL-7 in naïve-Treg survival and homeostatic 
proliferation. These findings are particularly relevant for 
understanding the impact of IL-7/IL-7Rα polymorphisms 
on autoimmunity [31], and the mechanisms underlying 
Treg expansion in lymphopenic settings, with implications 
for the therapeutic use of IL-7. 
Our data do not exclude the contribution of self-
peptide/MHC stimulation to the naïve-Treg proliferation, 
which may be particularly important given their 
enrichment in self-antigen reactivities [6]. However, TCR 
stimulation of naïve-Tregs has been associated with rapid 
acquisition of a memory phenotype, with the potential 
risk of contraction of the naïve compartment [1, 4]. Of 
note, the maintenance of murine naïve-like FoxP3+ CD4 
T-cells was recently demonstrated to be independent of 
TCR-driven signals [32]. 
Importantly, we showed that naïve-Treg 
proliferation in response to IL-7 or IL-2 was associated 
with preservation of the naïve-like phenotype, in parallel 
with the maintenance or even increase of regulatory 
markers. We further showed that prior exposure of naïve-
Tregs to IL-7 did not impair their suppressive capacity. 
IL-7, like IL-2, is known to induce PD-1 and PD-
L1 on Tconvs [33] and Tregs [20]. Our observations 
extended these reports, by showing that IL-7 up-regulated 
PD-L1, but not PD-1, on both naïve-Tregs and naïve-
Tconvs. These results suggest that IL-7 contributes not 
only to T-cell homeostasis, but also to the containment 
of immunopathology, by up-regulating the inhibitory 
molecule PD-L1 on naïve CD4 T-cells, irrespective of 
their FoxP3 status. On the other hand, this may have 
implications for tumor immunity, given the clinically 
relevant suppression of tumor specific responses mediated 
by the PD-1/PD-L1 pathway [34].
SLO are an important source of IL-7 [10, 17]. Our 
results from tonsil tissue, using both flow-cytometry and 
immunofluorescence, confirmed a high local naïve-Treg 
turnover, suggesting that SLO contain appropriate niches 
for naïve-Treg homeostasis. Nevertheless, more detailed 
studies are required to decipher the topography of naïve-
Tregs in SLO, as well as the contribution of their possible 
interactions with IL-7-producing stromal reticular cells, 
dendritic cells or IL-2-producing memory T-cells. 
Our data argue for the sufficiency of peripheral 
proliferation and survival to achieve long-term 
maintenance of the naïve-Treg compartment even in the 
absence of thymic output. These results in adults expand 
upon a recent report describing preservation of naïve-
Treg counts during short-term follow-up of children 
submitted to total thymectomy in early infancy [15]. 
Although a previous study showed a reduction of naïve-
Treg frequency within total Tregs [13], this was not related 
to an actual contraction of naïve-Tregs upon thymectomy, 
but rather to the relatively high frequency of total Tregs, as 
also observed in our study (Table 1; proportion of naïve-
Tregs within total Treg compartment: 11.60%[9.08-18.00] 
in thymectomized versus 14.85%[12.05-23.95] in healthy 
subjects, P = 0.3776). 
The increase in naïve-Treg cycling in 
thymectomized adults was more likely mediated by 
IL-7 than by self-peptide/MHC interaction, given the 
conserved frequency of CD31+ cells, which are typically 
lost following TCR stimulation [16], and maintained by 
IL-7 [17]. We further showed that the CD31+ subset of 
naïve-Tregs was preferentially expanded by IL-7 in-vitro, 
in agreement with our previous data generated with total 
naïve CD4 T-cells [17]. Adults thymectomized in infancy 
feature an unexpectedly low prevalence of autoimmune 
diseases and allergy [12], which may be related to the 
maintenance of the broadly-reactive naïve-Treg pool. 
To our knowledge, there are no published data 
specifically addressing the changes in the naïve-Treg 
compartment in individuals receiving IL-7 therapy. 
Nevertheless, an increase in total Treg numbers was 
documented in clinical trials, although the expansion 
of the Tconv compartment was much higher, leading to 
maintenance [35, 36] or a relative decrease [37-39] in Treg 
proportions. In agreement with our in-vitro data, naïve-
Treg expansion was reported upon IL-2 therapy [28, 40, 
41]. 
In severe lymphopenic settings associated with 
elevated serum IL-7 levels, such as HIV infection [42], 
there is an apparent preservation of circulating naïve-Tregs 
[43], raising the possibility that these cells are responding 
to IL-7. We did not find a correlation between the size 
of the naïve-Treg compartment and IL-7 serum levels 
in either our thymectomized individuals or the study 
population as a whole, which may be due to the narrow 
range of IL-7 levels (Table 1). Our data are also relevant in 
other lymphopenic settings, particularly in the context of 
immune reconstitution following hematopoietic stem cell 
transplantation, where IL-7-driven proliferation of naïve-
Tregs may help to control graft versus host disease. Our 
results support a model in which the increased availability 
of IL-7 in lymphopenic settings may contribute to the 
expansion of the naïve-Treg compartment, thereby helping 
prevent immunopathology in the context of a constrained 
TCR repertoire. 
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In conclusion, naïve-Tregs feature high turnover 
in healthy adults, which further increases to compensate 
the loss of thymic replenishment upon total thymectomy. 
Moreover, our data reveal a role for IL-7 in naïve-Treg 
maintenance, both through up-regulation of the survival 
molecule Bcl-2 and induction of PI3K/mTOR-mediated 
proliferation. Clinical use and evaluation of therapies 
targeting the IL-7 pathway should take into account the 
contribution of IL-7 to naïve-Treg homeostasis. 
MATERIALS AND METHODS
Study design
Blood was collected from healthy and age-matched 
adults thymectomized in infancy (Table 1). Complete 
thymectomy was confirmed based on the corrective cardiac 
surgery report and severely reduced levels of sjTREC. 
Patients with syndromatic cardiopathy were excluded. 
Circulating naïve-Tregs were further compared to their 
precursors, CD4SP thymocytes, isolated from thymic 
tissue obtained from children during routine corrective 
cardiac surgery. Tonsil tissue and blood collected at the 
same time from children submitted to tonsillectomy were 
used to study in parallel naïve CD4 T-cells in blood and 
SLO. All subjects/legal guardians gave written informed 
consent for blood and/or tissue sampling. Study was 
approved by Ethical Boards of Faculty of Medicine of 
University of Lisbon, and from Hospital de Santa Cruz for 
thymic tissue collection, Portugal.
Cell isolation
PBMCs were isolated from freshly-collected 
heparinized blood via Ficoll-Paque PLUS (GE Healthcare, 
Uppsala, Sweden). Total or naïve CD4 T-cells were 
subsequently purified by negative selection (purity 
>96%, StemCell Technologies, Grenoble, France). 
Naïve-Tregs (CD45RO─CD25highCD127─), naïve-
Tconvs (CD45RO─CD25─CD127high), and memory-
Tregs (CD45RO+CD25highCD127─) were sorted from 
purified CD4 T-cells using a FACSAria (purity >95%; 
BD Biosciences, San Jose, CA). Tonsillar mononuclear 
cells and thymocytes were recovered using Ficoll-Paque 
PLUS after mechanical dispersion of tonsil and thymic 
tissue. CD4SP thymocytes were subsequently purified as 
CD3highCD8─CD4+ cells using a FACSAria (purity >97%). 
Cell culture
Purified naïve CD4 T-cells, naïve-Tregs or naïve-
Tconvs, were cultured at 1x106 cells/ml in complete 
medium as described [17], with either IL-7 (10ng/ml; 
R&D Systems, Minneapolis, MN) or IL-2 (20IU/ml; 
NIH/AIDS Research and Reference Program, Division 
of AIDS, NIAID, Hoffman-La Roche), for up to 13 days, 
with media replacement at day 3 and day 7. Naïve CD4 
T-cell recovery per well was significantly higher upon 
culture with IL-7 than IL-2 (200,615[144,000-262,167] 
versus 95,958[60,063-178,125]; n = 16; P = 0.0006). 
In some experiments, anti-IL-2 blocking monoclonal 
antibody (clone 5334, 10µg/ml, R&D Systems) or isotype 
control IgG1 (10µg/ml, eBioscience, San Diego, CA) was 
added to cultures with IL-7. Cultures were also performed 
for 7 days in presence of PI3K inhibitor LY294002 
(10µM, Merck Biosciences, Nottingham, UK); mTOR 
inhibitor rapamycin (100nM, Sigma-Aldrich); or drug 
vehicle DMSO (Sigma-Aldrich). For serum deprivation 
experiments, purified CD4 T-cells were cultured for 
24 hours in medium without AB serum, or with 40% 
autologous serum alone or supplemented with IL-7, IL-
2, anti-IL-2 blocking monoclonal antibody, or isotype 
control. 
Flow-cytometry
Ex-vivo phenotypic analysis was performed in 
freshly collected whole blood. Eight-color staining 
was performed using monoclonal antibodies listed in 
Supplementary Table 1. Intracellular staining was done 
using eBioscience FoxP3 kit. At least 150,000 events 
were acquired for each sample on a BD LSRFortessa (BD 
Biosciences) and data analyzed using FlowJo software 
(TreeStar, Ashland, OR). Dead cells were excluded 
according to FSC/SSC characteristics and/or LifeDead 
staining. After lymphogate definition, doublets were 
excluded, and cells analyzed within the mentioned gates.
STAT5 phosphorylation
pSTAT5 was quantified in whole blood immediately 
after collection. After surface staining, red blood cells 
were lysed, and cells fixed and permeabilized using 
eBioscience FoxP3 protocol, followed by BD Cytofix and 
BD Phosflow (BD Biosciences), and 1 hour incubation 
at 4°C with anti-pSTAT5 monoclonal antibody and other 
intracellular markers (Supplementary Table 1). pSTAT5 
was also quantified upon stimulation of surface stained 
purified CD4 T-cells, with increasing concentrations 
of recombinant IL-7 (0.1/1/10/50ng/ml) or IL-2 
(2/20/100/200IU/ml) for 15 minutes at 37°C, as described 
[44]. 
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Thymidine analogue 5-ethynyl-2’-deoxy-uridine 
(EdU) incorporation
EdU (5µM) was added to cell cultures for 12 
hours. Immediately after collection, cells were surface 
and intracellularly stained, resuspended in ice-cold 
1% formaldehyde (15 minutes), kept on ice on 70% 
ethanol (10 minutes), and then washed several times in 
PBS with 0.05% Triton-X100 before detection of EdU-
substituted DNA using the Click-iT® EdU HCS Assay 
(Thermo Fischer Scientific) according to manufacturer´s 
instructions. 
Cytokine quantification
Cytokine production at the single-cell level was 
assessed after 4 hours stimulation with PMA+Ionomycin 
and Brefeldin A, as described [44]. Serum IL-7 levels were 
quantified using Human IL-7 Quantikine HS ELISA kit 
(R&D Systems) [42]. 
In vitro suppression assay
Purified naïve-Tregs were incubated with IL-7, IL-2, 
or medium alone for 4 hours followed by co-culture (ratio 
1:1) with autologous naïve-Tconvs labeled with CFSE, 
as described [17], stimulated with plate bound anti-CD3 
(0.5µg/ml, clone OKT3, eBiosciences) in the presence of 
irradiated autologous PBMCs (4000rad). CFSE intensity 
decline was assessed at day 4 by flow-cytometry; % 
of suppression of naïve-Tconv proliferation = [(% 
proliferating naïve-Tconvs plated alone - % proliferating 
naïve-Tconvs co-cultured with Treg)/ % proliferating 
naïve-Tconvs plated alone]x100.
 sjTREC quantification
A highly sensitive nested quantitative PCR assay 
(detection-limit 1copy/105 cells) was used as described 
[24]. Triplicate multiplex PCR amplification of sjTREC, 
together with the CD3γ chain was performed on lysed 
PBMCs; quantifications were then performed using a 
LightCycler™ in independent experiments, with the same 
first-round serial dilution standard curve. 
FOXP3 mRNA quantification
Total RNA (Zymo Research kits) was used to 
generate cDNA (Superscript III Reverse Transcriptase, 
Thermo Fischer Scientific). mRNA levels of FOXP3 
(primers/probe described in [45]), and GAPDH (Taqman 
Gene Expression Assay) were quantified in duplicates 
(ViiA 7 Real-Time PCR System, all from Thermo Fischer 
Scientific) using standard curves generated by serial 
dilutions of cDNA from pooled PBMCs for GAPDH and 
a plasmid with FOXP3 sequence. Relative copy numbers 
of FOXP3 were calculated upon normalization to GAPDH.
Immunofluorescence staining
Human tonsils were placed in OCT (VWR, Radnor, 
PA) and snap-frozen in liquid nitrogen. 3μm sections 
were stained overnight at 4°C using antibodies listed in 
Supplementary Table 1, and DAPI as a nuclear counter 
stain. Image processing was performed using FIJI 
software.
Statistical analysis
Statistical analysis was performed with Graph 
Prism Version 5.01 (GraphPad Software, San Diego, CA). 
The following tests were used: Friedman for variance; 
Wilcoxon-Signed Rank for pairwise comparisons; Mann-
Whitney for unpaired comparisons; Spearman’s coefficient 
for correlations. Results were expressed as median 
[interquartile range or range (n < 4)]. P-values < 0.05 were 
considered significant.
ACKNOWLEDGMENTS
We thank the sample donors for their collaboration; 
Cardiothoracic Department, Hospital de Santa Cruz, for 
thymus collection; ENT Department, Hospital de Santa 
Maria, for tonsil collection; R Tendeiro, R Azevedo, H 
Nunes-Cabaço, MC Pereira-Santos, and AI Pinheiro 
for technical assistance; B Silva-Santos for fruitful 
discussions. 
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
GRANT SUPPORT
This work was supported by Fundação para a 
Ciência e Tecnologia (FCT; POCI2010/IC/83068/2007 
to RMMV; PTDC/SAU-MIC/109786/2009 to AES), and 
Gulbenkian Foundation (96526/2009 to JF; P132532/2013 
to AES). SLS, ASA, RBF, ARP, PM and SMF received 
FCT scholarships. 
REFERENCES
1. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa 
A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, 
Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, 
et al. Functional delineation and differentiation dynamics 
Oncotarget12174www.impactjournals.com/oncotarget
of human CD4+ T cells expressing the FoxP3 transcription 
factor. Immunity. 2009; 30:899-911.
2. Liston A and Gray DH. Homeostatic control of regulatory 
T cell diversity. Nat Rev Immunol. 2014; 14:154-165.
3. Caramalho I, Nunes-Cabaco H, Foxall RB and Sousa AE. 
Regulatory T-Cell Development in the Human Thymus. 
Front Immunol. 2015; 6:395.
4. Booth NJ, McQuaid AJ, Sobande T, Kissane S, Agius 
E, Jackson SE, Salmon M, Falciani F, Yong K, Rustin 
MH, Akbar AN and Vukmanovic-Stejic M. Different 
proliferative potential and migratory characteristics 
of human CD4+ regulatory T cells that express either 
CD45RA or CD45RO. J Immunol. 2010; 184:4317-4326.
5. Seddiki N, Santner-Nanan B, Tangye SG, Alexander SI, 
Solomon M, Lee S, Nanan R and Fazekas de Saint Groth B. 
Persistence of naive CD45RA+ regulatory T cells in adult 
life. Blood. 2006; 107:2830-2838.
6. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS and 
Ayyoub M. A peripheral circulating compartment of natural 
naive CD4 Tregs. J Clin Invest. 2005; 115:1953-1962.
7. Caramalho I, Nunes-Silva V, Pires AR, Mota C, Pinto 
AI, Nunes-Cabaco H, Foxall RB and Sousa AE. Human 
regulatory T-cell development is dictated by Interleukin-2 
and -15 expressed in a non-overlapping pattern in the 
thymus. J Autoimmun. 2015; 56:98-110.
8. Smigiel KS, Richards E, Srivastava S, Thomas KR, Dudda 
JC, Klonowski KD and Campbell DJ. CCR7 provides 
localized access to IL-2 and defines homeostatically distinct 
regulatory T cell subsets. J Exp Med. 2014; 211:121-136.
9. Bains I, Antia R, Callard R and Yates AJ. Quantifying the 
development of the peripheral naive CD4+ T-cell pool in 
humans. Blood. 2009; 113:5480-5487.
10. den Braber I, Mugwagwa T, Vrisekoop N, Westera L, 
Mogling R, de Boer AB, Willems N, Schrijver EH, 
Spierenburg G, Gaiser K, Mul E, Otto SA, Ruiter 
AF, Ackermans MT, Miedema F, Borghans JA, et al. 
Maintenance of peripheral naive T cells is sustained by 
thymus output in mice but not humans. Immunity. 2012; 
36:288-297.
11. Sauce D, Larsen M, Fastenackels S, Duperrier A, Keller M, 
Grubeck-Loebenstein B, Ferrand C, Debre P, Sidi D and 
Appay V. Evidence of premature immune aging in patients 
thymectomized during early childhood. J Clin Invest. 2009; 
119:3070-3078.
12. Prelog M, Keller M, Geiger R, Brandstatter A, Wurzner R, 
Schweigmann U, Zlamy M, Zimmerhackl LB and Grubeck-
Loebenstein B. Thymectomy in early childhood: significant 
alterations of the CD4(+)CD45RA(+)CD62L(+) T cell 
compartment in later life. Clin Immunol. 2009; 130:123-
132.
13. Halnon NJ, Cooper P, Chen DY, Boechat MI and 
Uittenbogaart CH. Immune dysregulation after 
cardiothoracic surgery and incidental thymectomy: 
maintenance of regulatory T cells despite impaired 
thymopoiesis. Clin Dev Immunol. 2011; 2011:915864.
14. Sauce D, Larsen M, Fastenackels S, Roux A, Gorochov 
G, Katlama C, Sidi D, Sibony-Prat J and Appay V. 
Lymphopenia-driven homeostatic regulation of naive 
T cells in elderly and thymectomized young adults. J 
Immunol. 2012; 189:5541-5548.
15. Schadenberg AW, van den Broek T, Siemelink MA, Algra 
SO, de Jong PR, Jansen NJ, Prakken BJ and van Wijk F. 
Differential homeostatic dynamics of human regulatory 
T-cell subsets following neonatal thymectomy. J Allergy 
Clin Immunol. 2014; 133:277-280 e271-276.
16. Kimmig S, Przybylski GK, Schmidt CA, Laurisch K, 
Mowes B, Radbruch A and Thiel A. Two subsets of naive 
T helper cells with distinct T cell receptor excision circle 
content in human adult peripheral blood. J Exp Med. 2002; 
195:789-794.
17. Azevedo RI, Soares MV, Barata JT, Tendeiro R, Serra-
Caetano A, Victorino RM and Sousa AE. IL-7 sustains 
CD31 expression in human naive CD4+ T cells and 
preferentially expands the CD31+ subset in a PI3K-
dependent manner. Blood. 2009; 113:2999-3007.
18. Heninger AK, Theil A, Wilhelm C, Petzold C, Huebel N, 
Kretschmer K, Bonifacio E and Monti P. IL-7 abrogates 
suppressive activity of human CD4+CD25+FOXP3+ 
regulatory T cells and allows expansion of alloreactive and 
autoreactive T cells. J Immunol. 2012; 189:5649-5658.
19. Kim GY, Ligons DL, Hong C, Luckey MA, Keller HR, 
Tai X, Lucas PJ, Gress RE and Park JH. An in vivo IL-7 
requirement for peripheral Foxp3+ regulatory T cell 
homeostasis. J Immunol. 2012; 188:5859-5866.
20. Younas M, Hue S, Lacabaratz C, Guguin A, Wiedemann 
A, Surenaud M, Beq S, Croughs T, Lelievre JD and Levy 
Y. IL-7 modulates in vitro and in vivo human memory T 
regulatory cell functions through the CD39/ATP axis. J 
Immunol. 2013; 191:3161-3168.
21. Simonetta F, Gestermann N, Martinet KZ, Boniotto M, 
Tissieres P, Seddon B and Bourgeois C. Interleukin-7 
influences FOXP3+CD4+ regulatory T cells peripheral 
homeostasis. PLoS One. 2012; 7:e36596.
22. Schmaler M, Broggi MA, Lagarde N, Stocklin BF, King 
CG, Finke D and Rossi SW. IL-7R signaling in regulatory 
T cells maintains peripheral and allograft tolerance in mice. 
Proc Natl Acad Sci U S A. 2015; 112:13330-13335.
23. van Gent R, Schadenberg AW, Otto SA, Nievelstein RA, 
Sieswerda GT, Haas F, Miedema F, Tesselaar K, Jansen 
NJ and Borghans JA. Long-term restoration of the human 
T-cell compartment after thymectomy during infancy: a role 
for thymic regeneration? Blood. 2011; 118:627-634.
24. Dion ML, Sekaly RP and Cheynier R. Estimating thymic 
function through quantification of T-cell receptor excision 
circles. Methods Mol Biol. 2007; 380:197-213.
25. Himmel ME, MacDonald KG, Garcia RV, Steiner TS and 
Levings MK. Helios+ and Helios- cells coexist within the 
natural FOXP3+ T regulatory cell subset in humans. J 
Oncotarget12175www.impactjournals.com/oncotarget
Immunol. 2013; 190:2001-2008.
26. Dupont G, Demaret J, Venet F, Malergue F, Malcus C, 
Poitevin-Later F, Morel J and Monneret G. Comparative 
dose-responses of recombinant human IL-2 and IL-7 on 
STAT5 phosphorylation in CD4+FOXP3- cells versus 
regulatory T cells: a whole blood perspective. Cytokine. 
2014; 69:146-149.
27. Bugault F, Benati D, Mouthon L, Landires I, Rohrlich 
P, Pestre V, Theze J, Lortholary O and Chakrabarti LA. 
Altered responses to homeostatic cytokines in patients 
with idiopathic CD4 lymphocytopenia. PLoS One. 2013; 
8:e55570.
28. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, 
Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, Armand 
P, Blazar BR, Antin JH, Soiffer RJ and Ritz J. Low-dose 
interleukin-2 therapy restores regulatory T cell homeostasis 
in patients with chronic graft-versus-host disease. Sci 
Transl Med. 2013; 5:179ra143.
29. Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango 
D, Grimes HL and Singer A. Suppression of IL7Ralpha 
transcription by IL-7 and other prosurvival cytokines: a 
novel mechanism for maximizing IL-7-dependent T cell 
survival. Immunity. 2004; 21:289-302.
30. Nunes-Cabaco H, Caramalho I, Sepulveda N and Sousa AE. 
Differentiation of human thymic regulatory T cells at the 
double positive stage. Eur J Immunol. 2011; 41:3604-3614.
31. Dooms H. Interleukin-7: Fuel for the autoimmune attack. J 
Autoimmun. 2013; 45:40-48.
32. Levine AG, Arvey A, Jin W and Rudensky AY. Continuous 
requirement for the TCR in regulatory T cell function. Nat 
Immunol. 2014; 15:1070-1078.
33. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, 
O’Shea MA and Fauci AS. The common gamma-chain 
cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression 
of programmed death-1 and its ligands. J Immunol. 2008; 
181:6738-6746.
34. Topalian SL, Drake CG and Pardoll DM. Immune 
checkpoint blockade: a common denominator approach to 
cancer therapy. Cancer Cell. 2015; 27:450-461.
35. Sereti I, Dunham RM, Spritzler J, Aga E, Proschan MA, 
Medvik K, Battaglia CA, Landay AL, Pahwa S, Fischl 
MA, Asmuth DM, Tenorio AR, Altman JD, Fox L, Moir 
S, Malaspina A, et al. IL-7 administration drives T cell-
cycle entry and expansion in HIV-1 infection. Blood. 2009; 
113:6304-6314.
36. Perales MA, Goldberg JD, Yuan J, Koehne G, Lechner 
L, Papadopoulos EB, Young JW, Jakubowski AA, Zaidi 
B, Gallardo H, Liu C, Rasalan T, Wolchok JD, Croughs 
T, Morre M, Devlin SM, et al. Recombinant human 
interleukin-7 (CYT107) promotes T-cell recovery after 
allogeneic stem cell transplantation. Blood. 2012; 120:4882-
4891.
37. Levy Y, Sereti I, Tambussi G, Routy JP, Lelievre JD, 
Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez 
B, Rouzioux C, Avettand-Fenoel V, Croughs T, Beq S, 
Morre M, Poulin JF, et al. Effects of recombinant human 
interleukin 7 on T-cell recovery and thymic output in HIV-
infected patients receiving antiretroviral therapy: results of 
a phase I/IIa randomized, placebo-controlled, multicenter 
study. Clin Infect Dis. 2012; 55:291-300.
38. Sportes C, Hakim FT, Memon SA, Zhang H, Chua KS, 
Brown MR, Fleisher TA, Krumlauf MC, Babb RR, Chow 
CK, Fry TJ, Engels J, Buffet R, Morre M, Amato RJ, 
Venzon DJ, et al. Administration of rhIL-7 in humans 
increases in vivo TCR repertoire diversity by preferential 
expansion of naive T cell subsets. J Exp Med. 2008; 
205:1701-1714.
39. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo 
LT, Schwarz SL, Stetler-Stevenson M, Morton KE, 
Mavroukakis SA, Morre M, Buffet R, Mackall CL and 
Gress RE. IL-7 administration to humans leads to expansion 
of CD8+ and CD4+ cells but a relative decrease of CD4+ 
T-regulatory cells. J Immunother. 2006; 29:313-319.
40. Weiss L, Letimier FA, Carriere M, Maiella S, 
Donkova-Petrini V, Targat B, Benecke A, Rogge L 
and Levy Y. In vivo expansion of naive and activated 
CD4+CD25+FOXP3+ regulatory T cell populations in 
interleukin-2-treated HIV patients. Proc Natl Acad Sci U S 
A. 2010; 107:10632-10637.
41. Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski 
ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober 
A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS 
and Peterson LB. Sustained in vivo signaling by long-lived 
IL-2 induces prolonged increases of regulatory T cells. J 
Autoimmun. 2015; 56:66-80.
42. Albuquerque AS, Cortesao CS, Foxall RB, Soares RS, 
Victorino RM and Sousa AE. Rate of increase in circulating 
IL-7 and loss of IL-7Ralpha expression differ in HIV-1 and 
HIV-2 infections: two lymphopenic diseases with similar 
hyperimmune activation but distinct outcomes. J Immunol. 
2007; 178:3252-3259.
43. Foxall RB, Albuquerque AS, Soares RS, Baptista AP, 
Cavaleiro R, Tendeiro R, Gomes P, Victorino RM and 
Sousa AE. Memory and naive-like regulatory CD4+ T cells 
expand during HIV-2 infection in direct association with 
CD4+ T-cell depletion irrespectively of viremia. AIDS. 
2011; 25:1961-1970.
44. Albuquerque AS, Marques JG, Silva SL, Ligeiro D, Devlin 
BH, Dutrieux J, Cheynier R, Pignata C, Victorino RM, 
Markert ML and Sousa AE. Human FOXN1-deficiency 
is associated with alphabeta double-negative and FoxP3+ 
T-cell expansions that are distinctly modulated upon thymic 
transplantation. PLoS One. 2012; 7:e37042.
45. Pereira-Santos MC, Baptista AP, Melo A, Alves RR, Soares 
RS, Pedro E, Pereira-Barbosa M, Victorino RM and Sousa 
AE. Expansion of circulating Foxp3+)D25bright CD4+ 
T cells during specific venom immunotherapy. Clin Exp 
Allergy. 2008; 38:291-297.
